Letendre L, Hinemann V, Hoagland H C, Kovach J S
Med Pediatr Oncol. 1985;13(4):232-4. doi: 10.1002/mpo.2950130414.
Fourteen patients with refractory acute non-lymphocytic leukemia were entered into a dose-seeking trial of combination therapy with etoposide and amsacrine given daily for five consecutive days. There were three complete responses lasting 2 months, 3 months, and 10 months and two transient partial remissions. Dose-limiting toxicities were stomatitis and diarrhea. Prolonged aplasia occurred at the highest doses tested and appeared to result from repetitive doses of the combination given as maintenance. We recommend for induction and consolidation/intensification treatment VP-16, 125 mg/m2, and AMSA, 125 mg/m2, intravenously daily for 5 days. A reduction by at least 50% in the dose of each drug is recommended for maintenance of complete remissions.
14例难治性急性非淋巴细胞白血病患者进入一项剂量探索性试验，接受依托泊苷和安吖啶联合治疗，连续5天每日给药。有3例完全缓解，持续时间分别为2个月、3个月和10个月，还有2例短暂部分缓解。剂量限制性毒性为口腔炎和腹泻。在测试的最高剂量时出现了长期再生障碍，似乎是由于作为维持治疗重复给予联合用药所致。我们建议诱导和巩固/强化治疗时，依托泊苷125mg/m²、安吖啶125mg/m²，静脉滴注，每日1次，共5天。建议完全缓解后维持治疗时，每种药物剂量至少减少50%。
